Metabolic and hormonal derangements in pulmonary hypertension: From mouse to man

International Journal of Clinical Practice

Volumn 64, Issue SUPPL. 168, 2010, Pages 5-13

  Pugh, M E ^a   Hemnes, A R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; ESTROGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGESTERONE; SEX HORMONE;

DISEASE COURSE; DYSLIPIDEMIA; ESTROGEN METABOLISM; HORMONE DEFICIENCY; HORMONE METABOLISM; HUMAN; INSULIN RESISTANCE; LUNG BLOOD VESSEL; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78649258232     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02523.x     Document Type: Review

References (80)

1. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010; 35: 1079 - 87.
2. Humbert M, Sitbon O, Yaici A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549 - 55.
3. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial and anorexigen associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156 - 63.
4. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension. Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164 - 72.
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: S43 - 54.
6. Hansmann G, Wagner RA, Schellong S, et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007; 115: 1275 - 84.
7. Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009; 33: 318 - 24.
8. Heresi GA, Aytekin M, Newman J, et al. Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 661 - 68.
9. Summer R, Fiack CA, Ikeda Y, et al. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol 2009; 297: L432 - 8.
10. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023 - 30.
11. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376 - 87.
12. Austin ED, Cogan JD, West JD, et al. Alterations in estrogen metabolism: implications for higher penetrance of FPAH in females. Eur Respir J 2009; 34: 1093 - 9.
13. Pugh ME, Hemnes AR,. Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Womens Health (Lond Engl) 2010; 6: 285 - 96.
14. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640 - 5.
15. Ervin RB,. Prevalence of metabolic syndrome among adults 20-years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; May 5: 1 - 7.
16. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010; 375: 181 - 3.
17. Cameron AJ, Boyko EJ, Sicree RA, et al. Central obesity as a precursor to the metabolic syndrome in the AusDiab study and Mauritius. Obesity (Silver Spring) 2008; 16: 2707 - 16.
18. Koh KK, Han SH, Quon MJ,. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46: 1978 - 85.
19. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996; 35: 989 - 93.
20. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136 - 42.
21. Torres JL, Ridker PM,. High sensitivity C-reactive protein in clinical practice. Am Heart Hosp J 2003; 1: 207 - 11.
22. Maury E, Brichard SM,. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1 - 16.
23. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79 - 83.
24. Cubbon RM, Kahn MB, Wheatcroft SB,. Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clin Sci (Lond) 2009; 117: 173 - 90.
25. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888 - 904.
26. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO,. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006; 95: 136 - 47.
27. Saylor PJ, Smith MR,. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009; 181: 1998 - 2006; discussion 2007-1998.
28. Merki-Feld GS, Imthurn B, Rosselli M, et al. Serum concentrations of high-molecular weight adiponectin and their association with sex steroids in premenopausal women. Metabolism 2010; epub 21 Jan 2010.
29. Travers SH, Jeffers BW, Eckel RH,. Insulin resistance during puberty and future fat accumulation. J Clin Endocrinol Metab 2002; 87: 3814 - 8.
30. Moran A, Jacobs DR Jr, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 1999; 48: 2039 - 44.
31. Hamid R, Cogan JD, Hedges LK, et al. Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum Mutat 2009; 30: 649 - 54.
32. Machado RD, Pauciulo MW, Thomson JR, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68: 92 - 102.
33. Du L, Sullivan CC, Chu D, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003; 348: 500 - 9.
34. Galetto R, Albajar M, Polanco JI, et al. Identification of a peroxisome-proliferator-activated-receptor response element in the apolipoprotein E gene control region. Biochem J 2001; 357: 521 - 7.
35. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003; 100: 15712 - 7.
36. Hevener AL, He W, Barak Y, et al. Muscle-specific Pparg deletion causes insulin resistance. Nat Med 2003; 9: 1491 - 7.
37. Lehrke M, Lazar MA,. The many faces of PPARgamma. Cell 2005; 123: 993 - 9.
38. Duan SZ, Ivashchenko CY, Usher MG, et al. PPAR-gamma in the cardiovascular system. PPAR Res 2008; 2008: 745 - 804.
39. Itoh T, Nagaya N, Ishibashi-Ueda H, et al. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology 2006; 11: 158 - 63.
40. Farber HW, Loscalzo J,. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655 - 65.
41. Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 2003; 92: 1162 - 9.
42. Geraci MW, Moore M, Gesell T, et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ Res 2001; 88: 555 - 62.
43. Hansson GK,. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685 - 95.
44. Hansmann G, De Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008; 118: 1846 - 57.
45. Trayhurn P, Bing C, Wood IS,. Adipose tissue and adipokines - energy regulation from the human perspective. J Nutr 2006; 136: 1935S - 9S.
46. Hansmann G, Rabinovitch M,. The protective role of adiponectin in pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol 2010; 298: L1 - 2.
47. Maruna P, Lindner J, Kubzova KM,. Leptin and soluble leptin receptor changes after pulmonary endarterectomy: relations to cortisol and cytokine network. Physiol Res 2009; 58: 569 - 76.
48. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226 - 8.
49. Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812 - 7.
50. Swarbrick MM, Havel PJ,. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6: 87 - 102.
51. Medoff BD, Okamoto Y, Leyton P, et al. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 2009; 41: 397 - 406.
52. Guignabert C, Alvira CM, Alastalo TP, et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1082 - 90.
53. Loyd JE, Butler MG, Foroud TM, et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93 - 7.
54. Lahm T, Crisostomo PR, Markel TA, et al. Selective estrogen receptor-alpha and estrogen receptor-beta agonists rapidly decrease pulmonary artery vasoconstriction by a nitric oxide dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2008; 295: R1486 - 93.
55. Lahm T, Crisostomo PR, Markel TA, et al. The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med 2008; 36: 2174 - 83.
56. Lahm T, Patel KM, Crisostomo PR, et al. Endogenous estrogen attenuates pulmonary artery vasoreactivity and acute hypoxic pulmonary vasoconstriction: the effects of sex and menstrual cycle. Am J Physiol Endocrinol Metab 2007; 293: E865 - 71.
57. Tofovic SP, Zhang X, Jackson EK, et al. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol 2006; 45: 358 - 67.
58. Moore LG, McMurtry IF, Reeves JT,. Effects of sex hormones on cardiovascular and hematologic responses to chronic hypoxia in rats. Proc Soc Exp Biol Med 1978; 158: 658 - 62.
59. Rabinovitch M, Gamble WJ, Miettinen OS, et al. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol 1981; 240: H62 - 72.
60. McMurtry IF, Frith CH, Will DH,. Cardiopulmonary responses of male and female swine to simulated high altitude. J Appl Physiol 1973; 35: 459 - 62.
61. Resta TC, Kanagy NL, Walker BR,. Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am J Physiol Lung Cell Mol Physiol 2001; 280: L88 - 97.
62. Tofovic SP, Zhang X, Jackson EK, et al. 2-Methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol 2009; 51: 190 - 7.
63. Tofovic SP, Zhang X, Jackson EK, et al. 2-Methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats. Vascul Pharmacol 2009; 51: 190 - 7.
64. Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073 - 80.
65. Vander Heiden MG, Cantley LC, Thompson CB,. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029 - 33.
66. Warburg OPK, Negelein E,. Ueber den Stoffwechsel der Tumor. Biochem Z 1924; 152: 319 - 44.
67. Robbins IM, Newman JH, Johnson RF, et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009; 136: 31 - 6.
68. Pugh M,. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181: A4813.
69. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143 - 421.
70. Gonzalez-Diez M, Rodriguez C, Badimon L, et al. Prostacyclin induction by high-density lipoprotein (HDL) in vascular smooth muscle cells depends on sphingosine 1-phosphate receptors: effect of simvastatin. Thromb Haemost 2008; 100: 119 - 26.
71. Toikka JO, Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 1999; 147: 133 - 8.
72. O'Connell BJ, Genest J Jr,. High-density lipoproteins and endothelial function. Circulation 2001; 104: 1978 - 83.
73. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216 - 23.
74. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103 - 10.
75. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196 - 203.
76. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835 - 42.
77. Chung L, Liu J, Parsons L, et al. Characterization of Connective Tissue Disease Associated Pulmonary Arterial Hypertension from the Reveal Registry: identifying systemic sclerosis as a unique phenotype. Chest 2010; epub 27 May 2010.
78. Ventetuolo CEOP, Bluemke DA, Tandri H, et al. Sex hormones and the right ventricle: the MESA-right ventricle study. Abstract Presentation, Proceedings of the American Thoracic Society, 2009.
79. Rajkumar R, Konishi K, Richards TJ, et al. Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010; 298: H1235 - 48.
80. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6 (Suppl. 2): 51S - 209S.